Vertex Pharmaceuticals reports third-quarter 2026 results
Vertex Pharmaceuticals reported its financial results for the third quarter of 2026, recording non-GAAP net income of $1.2 billion.

VRTX Health Care · 1 analysis · 15 expectations tracked
Vertex Pharmaceuticals Inc / MA reported $3.4B in revenue (+11.8% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 15 open management expectations for this company. 2 insider sales recorded. Its latest periodic filing added 2 new risk factors.
Vertex Pharmaceuticals reported its financial results for the third quarter of 2026, recording non-GAAP net income of $1.2 billion.
VERTEX PHARMACEUTICALS INC / MA: 5 recorded developments from 1 official source in 2026-10.
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $3.4B | $3.1B | +11.8% |
| Operating income quarter | $713M | $1.2B | -39.9% |
| Net income quarter | $654M | $1.1B | -39.6% |
| Diluted EPS quarter | $2.56 | $4.20 | -39.0% |
| Operating cash flow year to date | $3.2B | $3.1B | +2.0% |
| Cash and cash equivalents balance | $5B | $5.1B | -2.1% |
| Long-term debt balance | $3.5B | $0 | — |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Vertex Pharmaceuticals Inc / MA VRTX | $3.4B | +11.8% | 20.7% |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Vertex plans to advance VX-017 into pivotal development.
Not yet checked against later reports.
Vertex is on track to share results from the gMG study in the first half of 2027.
Not yet checked against later reports.
Vertex expects to advance VX-017 into pivotal development in 2027.
Not yet checked against later reports.
The company plans to complete enrollment in the Phase 2 study of VX-993 in DPN.
Not yet checked against later reports.
Vertex expects to complete enrollment in the atumelnant trial in the first quarter of 2027.
Not yet checked against later reports.
Vertex is on track to share interim results from the GALILEO study.
Not yet checked against later reports.
Vertex plans for the Phase 3 trial of atumelnant in adults with CAH, with expectations to complete enrollment in the first quarter of 2027.
Not yet checked against later reports.
Raised full year 2026 total revenue guidance to $13.15 billion to $13.25 billion.
Not yet checked against later reports.
Vertex expects to complete dosing in the VX-670 trial for DM1 and share interim results.
Not yet checked against later reports.
Vertex expects to begin PALSONIFY launches in European markets in the second half of 2027.
Not yet checked against later reports.
The company expects $500 million or more in revenue from CASGEVY and JOURNAVX combined, and $40 million to $50 million in revenue from PALSONIFY.
Not yet checked against later reports.
Vertex is on track to share data from the inaxaplin interim analysis in early 2027.
Not yet checked against later reports.
The company expects to begin launches for PALSONIFY in European markets.
Not yet checked against later reports.
The company plans to share results from the suzetrigine Phase 3 studies in DPN.
Not yet checked against later reports.
The company plans to complete enrollment in both Phase 3 studies of suzetrigine in DPN.
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
The 10-Q filed November 3, 2026 compared with the 10-Q filed August 4, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| October 20, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| September 1, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|---|---|---|---|---|---|
| November 16, 2026 | Thornberry Nancy | Planned sale 10b5-1 plan | 1,000 | — | $547,860 | SEC |
| November 16, 2026 | Bhatia Sangeeta N. | Planned sale 10b5-1 plan | 271 | — | $148,470 | SEC |
| November 12, 2026 | Charles F Wagner Jr | Sale 10b5-1 plan notice filed | 15,286 | $547.87 | $8,374,741 | SEC |
| November 6, 2026 | Reshma Kewalramani | Sale 10b5-1 plan notice filed | 11,866 | $531.53 | $6,307,135 | SEC |
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 23,803,111 | $12,444,504,450 | -1.3% | Q3 2026 |
| Capital Research Global Investors | 17,814,302 | $9,313,657,644 | -8.6% | Q3 2026 |
| State Street | 12,024,456 | $6,286,505,841 | +1.3% | Q3 2026 |
| Geode Capital Management | 6,081,969 | $3,165,506,588 | +1.1% | Q3 2026 |
| Wellington Management | 3,363,758 | $1,758,606,320 | +3.6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 2,971,681 | $1,476,123,103 | — | Q2 2026 |
| Fidelity (FMR) | 1,541,000 | $805,650,363 | +5.8% | Q3 2026 |
| Citadel Advisors | 1,032,674 | $539,892,294 | +102.3% | Q3 2026 |
| Millennium Management | 567,655 | $296,775,711 | +21.2% | Q3 2026 |
| Renaissance Technologies | 396,768 | $207,434,278 | +24.0% | Q3 2026 |
| Two Sigma Investments | 203,123 | $106,194,736 | -28.7% | Q3 2026 |
| Bridgewater Associates | 34,915 | $18,253,911 | +221.4% | Q3 2026 |
| D. E. Shaw & Co. | 5,631 | $2,943,944 | +81.4% | Q3 2026 |
| T. Rowe Price | 1,733,342 | $906,209 | +0.3% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.